1. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

drug target

" in MedChemExpress (MCE) Product Catalog:

384

Inhibitors & Agonists

153

Screening Libraries

2

Fluorescent Dye

132

Biochemical Assay Reagents

47

Peptides

31

Inhibitory Antibodies

14

Natural
Products

8

Isotope-Labeled Compounds

5

Click Chemistry

50

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139819

    Biochemical Assay Reagents Others
    MPEG-PLA (PEG MW 3000 & PLA MW 50,000) is a block copolymer, which can be used to preparenanoparticles for targeted drug delivery .
    MPEG-PLA (PEG MW 3000 & PLA MW 50,000)
  • HY-147354

    LYTACs Cardiovascular Disease
    TriGalNAc CBz is a GalNAc derivative and tri-GalNAc is an asialoglycoprotein receptor (ASGPR) ligand. TriGalNAc CBz can be used for mRNA drug delivery as well as lysosomal targeted chimerism (LYTAC) studies .
    TriGalNAc CBz
  • HY-P10128
    GE11
    1 Publications Verification

    Biochemical Assay Reagents Inflammation/Immunology
    GE11 is a active peptide and combines with colloidal drug delivery systems as smart carriers for antitumor drugs and can be used for cancer study .
    GE11
  • HY-170587

    Drug-Linker Conjugates for ADC Cancer
    Glucocorticoid receptor drug-linke 1 is a drug-linker conjugate, that can be used for synthesis of BDCA2-targeting ADC .
    Glucocorticoid receptor drug-linke 1
  • HY-166975

    pSar 100

    Biochemical Assay Reagents Others
    Polysarcosine 100 (pSar 100) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 100 can be used in drug delivery research .
    Polysarcosine 100
  • HY-166972

    pSar 50

    Biochemical Assay Reagents Others
    Polysarcosine 50 (pSar 50) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 50 can be used in drug delivery research .
    Polysarcosine 50
  • HY-166973

    pSar 20

    Biochemical Assay Reagents Others
    Polysarcosine 20 (pSar 20) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 20 can be used in drug delivery research .
    Polysarcosine 20
  • HY-166974

    pSar 150

    Biochemical Assay Reagents Others
    Polysarcosine 150 (pSar 150) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 150 can be used in drug delivery research .
    Polysarcosine 150
  • HY-139818

    Biochemical Assay Reagents Others
    Mal-PEG-PLA (PEG MW 3000 & PLA MW 70,000) is a block copolymer, which can be used to preparenanoparticles and micelles for targeted drug delivery .
    Mal-PEG-PLA (PEG MW 3000 & PLA MW 70,000)
  • HY-155321

    Prostaglandin Receptor Cancer
    NXT-10796 is orally active, intestinally restricted EP4 receptor agonist .
    NXT-10796
  • HY-156432

    Anaplastic lymphoma kinase (ALK) mTOR PARP Caspase Cancer
    ALK-IN-26 is an ALK inhibitor with IC50 value of 7.0 μM for ALK tyrosine kinase. ALK-IN-26 has good pharmacokinetic properties and blood-brain barrier (BBB) permeability. ALK-IN-26 can induce apoptosis, autophagy and necrosis. ALK-IN-26 can be used in glioblastoma studies .
    ALK-IN-26
  • HY-164296

    ADC Linker Cancer
    SMP-96745 is a dual-drug targeting linker-drug conjugate and can be used for study of cancer .
    SMP-96745
  • HY-132994

    Biochemical Assay Reagents Others
    TVD-0003510 is a carboxamide derivative, and involves in synthesis of (2-((6-(2-aminopyrimidine-5-carboxamido)-8-methoxy-3,4-dihydro-2H-pyrimido[1,2-c]quinazolin-9-yl)oxy)ethyl)piperazine-l-carboxylate (C51), as a part of tert-butyl2-(4-hydroxyphenyl)acetate .
    TVD-0003510
  • HY-162908

    TRP Channel Cannabinoid Receptor Neurological Disease
    TRPV1/CB2 agonist 1 (compound 41) is a TRPV1/CB2 agonist, with an EC50 of 26.8 μM for hTRPV1. TRPV1/CB2 agonist 1 can be used in nervous system related research .
    TRPV1/CB2 agonist 1
  • HY-144424

    Trk Receptor Cancer
    Trk-IN-11 (Compound 14h) is a potent inhibitor of TRK (IC50 = 1.4, 1.8 nM, against TrkA, TrkA G595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-11 has the potential for the research of cancer disease .
    Trk-IN-11
  • HY-P10501A

    Antifolate Cancer
    FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .
    FRα-targeting peptide C7 TFA
  • HY-P10501

    Antifolate Cancer
    FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .
    FRα-targeting peptide C7
  • HY-160182

    ADC Linker Glucocorticoid Receptor Inflammation/Immunology
    INX-P is glucocorticosteroid-target antibody drug conjugate (ADC) .
    INX-P
  • HY-N0402
    Artemether
    1 Publications Verification

    Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224

    Parasite Infection Inflammation/Immunology Cancer
    Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria .
    Artemether
  • HY-144423

    Trk Receptor Cancer
    Trk-IN-10 (Compound 14j) is a potent inhibitor of TRK (IC50 = 0.86, 6.92 nM, against TrkA, TrkA G595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-10 (IC50 = 350 nM against ALK) has a higher selectivity of Trk inhibition, which may be of great significance for reducing toxicity .
    Trk-IN-10
  • HY-P2218

    Radionuclide-Drug Conjugates (RDCs) CXCR Cancer
    Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Anditixafortide
  • HY-101993

    Amino Acid Derivatives Others
    Nap-FF is a cell-penetrating dipeptide that can be used in the preparation of hydrogel chemosensors and in the research of targeted drug delivery .
    Nap-FF
  • HY-W440915

    Liposome Others
    DSPE-PEG-FITC, MW 2000 is a fluorescein attached PEG lipid. It can be used to prepare liposomes as drug carrier in targeted drug delivery. The polymer is modified with fluorescein (green) dye which can be used for staining cells, tissues, biomarkers, or nanoparticles.
    DSPE-PEG-FITC (MW 2000)
  • HY-W440917

    Liposome Others
    DSPE-PEG-FITC, MW 5000 is a fluorescein attached PEG lipid. It can be used to prepare liposomes as drug carrier in targeted drug delivery. The polymer is modified with fluorescein (green) dye which can be used for staining cells, tissues, biomarkers, or nanoparticles.
    DSPE-PEG-FITC (MW 5000)
  • HY-W440916

    Liposome Others
    DSPE-PEG-FITC, MW 3400 is a fluorescein attached PEG lipid. It can be used to prepare liposomes as drug carrier in targeted drug delivery. The polymer is modified with fluorescein (green) dye which can be used for staining cells, tissues, biomarkers, or nanoparticles.
    DSPE-PEG-FITC (MW 3400)
  • HY-154844

    Biochemical Assay Reagents Cancer
    FAP Ligand 1 (FL), a high-affinity FAP small-molecule ligand, is used to target attached drugs to FAP-expressing fibroblasts and can be used in radiation imaging studies of targeted cancers .
    FAP Ligand 1
  • HY-128937

    Liposome Folate Receptor (FR) Cancer
    EC1454 is a peptide compound with anticancer activity that targets folate receptor-expressing cancers. EC1454 is a folate-tubulysin conjugate that can be used to prepare drug delivery conjugates for targeted therapy .
    EC1454
  • HY-N144101

    SARS-CoV Infection
    SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 M pro with an IC50 value of 72.07 nM. The main protease (M pro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19 .
    SARS-CoV MPro-IN-2
  • HY-144880

    3-Aminophenyl Hemiasterlin

    ADC Payload Microtubule/Tubulin P-glycoprotein Cancer
    SC209 (3-Aminophenyl Hemiasterlin) is a 3-aminophenyl hemiasterlin derivative that serves as a cytotoxin for ADCs, targeting tubulin. SC209 has reduced potential for drug efflux via P-glycoprotein 1 drug pump compared with other tubulin-targeting payloads. SC209 exhibits antitumor activity and can be used in the synthesis of ADC molecules .
    SC209
  • HY-13631D
    Dxd
    Maximum Cited Publications
    12 Publications Verification

    Exatecan derivative for ADC

    Topoisomerase ADC Payload Cancer
    Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
    Dxd
  • HY-112111

    Biochemical Assay Reagents Cancer
    Poly-L-Glutamic acid (MW 700000) is biochemical reagent.Poly-L-Glutamic acid can be used as the drug carrier for targeted delivery of anticancer agents .
    Poly-L-Glutamic acid (MW 700000)
  • HY-P9921
    Trastuzumab emtansine
    3 Publications Verification

    Ado-Trastuzumab emtansine; PRO132365; T-DM 1

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .
    Trastuzumab emtansine
  • HY-P9921A
    Trastuzumab emtansine (solution)
    3 Publications Verification

    Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .
    Trastuzumab emtansine (solution)
  • HY-172356A

    Biochemical Assay Reagents Others
    Biotin-PEG-NH2 (Mn 5300) can be used for biotinylation of polymerized worm micelles for targeting and drug transfer to cells .
    Biotin-PEG-NH2 (MW 5300)
  • HY-172356

    Biochemical Assay Reagents Others
    Biotin-PEG-NH2 (Mn 3700) can be used for biotinylation of polymerized worm micelles for targeting and drug transfer to cells .
    Biotin-PEG-NH2 (MW 3700)
  • HY-102001

    ADC Payload Cancer
    Tomaymycin DM, a DNA alkylator, is a derivative of Tomaymycin, it is a PBD dimer, which is attached to tumor targeting antibodies to create antibody-drug conjugates (ADCs).
    Tomaymycin DM
  • HY-141594

    Microtubule/Tubulin Cancer
    Modified MMAF, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). Modified MMAF can be used for the targeted research of cancer .
    Modified MMAF
  • HY-135125

    ADC Payload Cancer
    DC4, an ADC cytotoxin, can be used in the synthesis of antibody-drug conjugate (ADC). DC4 can be used for the targeted treatment of cancer .
    DC4
  • HY-41049

    ADC Linker Cancer
    NSC 135130 (compound 11a) is a BOC-protected ADC linker that can be linked to tubulin-targeting inhibitors.Can be used to synthesize drug conjugates .
    NSC 135130
  • HY-174972A

    Biochemical Assay Reagents Others
    mPEG-DPPE (MW 5000) is an amphiphilic phospholipid-modified polymer that can be used to prepare lipid nanoparticles or liposomes for targeted drug delivery applications .
    mPEG-DPPE (MW 5000)
  • HY-174972

    Biochemical Assay Reagents Others
    mPEG-DPPE (MW 1000) is an amphiphilic phospholipid-modified polymer that can be used to prepare lipid nanoparticles or liposomes for targeted drug delivery applications .
    mPEG-DPPE (MW 1000)
  • HY-P99719

    BAY 1129980; Anti-C4.4a antibody-drug conjugates

    Antibody-Drug Conjugates (ADCs) Cancer
    Lupartumab Amadotin (BAY 1129980) is an antibody–drug conjugate (ADC) consisting of a fully human C4.4A (LYPD3)-targeting mAb (BAY 1135626) (HY-147281) conjugated to a novel, highly potent derivative of the microtubule-disrupting cytotoxic drug auristatin via a noncleavable alkyl hydrazide linker. Lupartumab Amadotin can be used for the research of non-small cell lung cancer .
    Lupartumab Amadotin
  • HY-115415

    Liposome Others
    1,2-Distearoyl-sn-glycero-3-phosphate, sodium salt is a phospholipid commonly used as a component of liposome formulations and drug delivery systems. 1,2-Distearoyl-sn-glycero-3-phosphate, sodium salt has unique chemical properties that make it an effective tool for encapsulating drugs and delivering them to specific targets in the body. It acts as a stabilizer and emulsifier, which can improve the solubility and bioavailability of drugs.
    1,2-Distearoyl-sn-glycero-3-phosphate sodium
  • HY-115822

    Amino Acid Decarboxylase Glutathione S-transferase Metabolic Disease
    α-Fluoromethylhistidine dihydrochloride is a potent irreversible inhibitor of histidine decarboxylase (HDC) and glutathione S-transferase, demonstrating significant potential in studying histidine metabolism and drug metabolism processes. α-Fluoromethylhistidine dihydrochloride offers an effective approach to inhibit enzymes involved in these metabolic pathways. α-Fluoromethylhistidine dihydrochloride has implications for drug development by revealing off-target effects that may influence physiological drug metabolism and elimination mechanisms.
    α-Fluoromethylhistidine dihydrochloride
  • HY-P10027

    Antibiotic Bacterial Infection
    Clovibactin is an antibiotic for drug-resistant bacterial pathogens without detectable resistance. Clovibactin TFA inihibits cell wall synthesis by targeting pyrophosphate of peptidoglycan precursors .
    Clovibactin
  • HY-147546

    Bacterial Infection
    Antibacterial agent 107 (compound 14) is a potent antibacterial agent. Antibacterial agent 107 shows potent antibacterial activity against Gram-positive bacteria, with a MIC of 1.56 μg/mL (MRSA). Antibacterial agent 107 exhibits low hemolytic activity, high membrane selectivity, and rapid bactericidal activity. Antibacterial agent 107 shows effective in vivo efficacy in the murine model of bacterial keratitis caused by Staphylococcus aureus ATCC29213 .
    Antibacterial agent 107
  • HY-138131

    SOD Neurological Disease
    SOD1-Derlin-1 inhibitor-1 (compound 56-20) is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor-1 inhibits SOD1 G93A-Derlin-1 complex with an IC50 value of 7.11 μM. SOD1-Derlin-1 inhibitor-1 can be used for the research of amyotrophic lateral sclerosis .
    SOD1-Derlin-1 inhibitor-1
  • HY-123982

    SOD Neurological Disease
    SOD1-Derlin-1 inhibitor-2 (compound 56-59) is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor-2 attenuates the interactions between Derlin-1 and SOD1 mut. SOD1-Derlin-1 inhibitor-2 can be used for the research of amyotrophic lateral sclerosis (ALS) .
    SOD1-Derlin-1 inhibitor-2
  • HY-118326

    Autophagy Cancer
    MRT 68601 is a potent TBK1 inhibitor with the activity of inhibiting autophagosome formation in lung cancer cells. MRT 68601 may have potential effects against targets associated with host-dependent factors identified in SARS-CoV-2 infection. The drug targets involved in MRT 68601 are related to existing FDA-approved drugs and compounds in clinical trials, which can provide support for the development of broad-spectrum antiviral therapies .
    MRT 68601
  • HY-13631DS

    Exatecan-d5 derivative for ADC

    Topoisomerase ADC Payload Cancer
    Dxd-d5 is a deuterium labeled Dxd. Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) .
    Dxd-d5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: